Medico Remedies Ltd - 540937 - Disclosure of Voting results of Postal Ballot (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Medico Remedies Ltd has informed BSE regarding the details of Voting results of Postal Ballot, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here Medico Remedies Ltd - 540937 - Disclosure On E-Voting Results On Resolutions Passed Through Postal Ballot By Medico Remedies Limited
In furtherance to our communication dated 20th May, 2022 in connection with the Postal Ballot conducted by the Company for seeking approval of the Shareholders for matters set out in the Notice of Postal Ballot dated 20th May, 2022 and pursuant to Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the following: 1. Voting Results as required pursuant to Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 marked as Annexure-I; and 2. Scrutinizers' Report on e-Voting Results on resolutions passed through Postal Ballot marked as Annexure-II The said resolutions as set out in Postal Ballot Notice is passed with the requisite majority and is deemed to be passed on the last date of the e-voting, i.e. 21st June, 2022. Medico Remedies Ltd - 540937 - MIGRATION OF EQUITY SHARES OF MEDICO REMEDIES LIMITED FROM SME PLATFORM OF BSE LIMITED (BSE SME) TO MAIN BOARD OF BSE LIMITED AND NSE LIMITED
Dear Sir/Madam, Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that BSE has issued the circular for the migration vide circular no. 20220524-10 dated May 24, 2022 stating that Company will be migrated & admitted to dealings on the Main Board of Bombay Stock Exchange Limited with effect from Thursday, May 26, 2022. Simultaneously, we have also received the letter from National Stock Exchange of India Limited dated May 24, 2022 stating, that equity shares of the Company shall be listed and admitted to dealings on NSE Limited with effect from Thursday, May 26, 2022. We are enclosing herewith both the circulars. We request you to kindly take the same on your record Medico Remedies Ltd - 540937 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In compliance with Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the newspaper advertisements published in Active Times (English Edition) and in Mumbai Lakshdeep (Marathi Edition) on 22nd May, 2022 for information on completion of dispatch of Notice of Postal Ballot and details on remote e-voting Medico Remedies Ltd - 540937 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Notice of Postal Ballot. The Notice is being sent to all the Members, whose names appear in the Register of Members / list of Beneficial Owners as received from National Securities Depository Limited and Central Depository Services (India) Limited and whose email IDs are registered with the Company / Depositories as on Friday, 13th May, 2022. The voting period will commence from Monday, 23rd May, 2022 at 9.00 a.m. IST and end on Tuesday, 21st June, 2022 at 5.00 p.m. IST Medico Remedies Ltd - 540937 - Audited Standalone Financial Results Of The Company For The Half-Year Ended 31St March, 2022 And Audited Financial Statement For The Year Ended On 31St March, 2022 Along With The Auditor'S Report Thereon
Audited Standalone Financial Results of the Company for the half-year ended 31st March, 2022 and Audited Financial Statement for the year ended on 31st March, 2022 along with the Auditor's Report thereon Medico Remedies Ltd - 540937 - Audited Standalone Financial Results Of The Company For The Half-Year Ended 31St March, 2022 And Audited Financial Statement For The Year Ended On 31St March, 2022 Along With The Auditor'S Report Thereon
Audited Standalone Financial Results of the Company for the half-year ended 31st March, 2022 and Audited Financial Statement for the year ended on 31st March, 2022 along with the Auditor's Report thereon Medico Remedies Ltd - 540937 - Board Meeting Outcome for Outcome Of The Board Meeting Held Today
we hereby inform you that the Board of Directors of our Company at their meeting held today i.e. 20th May, 2022 has, inter alia considered and approved the following: 1. Audited Standalone Financial Results of the Company for the half-year ended 31st March, 2022 and Audited Financial Statement for the year ended on 31st March, 2022 along with the Auditor's Report thereon. 2. Reappointment of Mr. Harshit Mehta as a Managing Director for a term of three consecutive years 3. Reappointment of Mr. Ramesh Rughani as an Independent Director for a second term of five consecutive years 4. Reappointment of Mr. Deepak Vekaria as an Independent Director for a second term of five consecutive years 5. Reappointment of Mr. Bharat Rathod as an Independent Director for a second term of five consecutive years 6. Increase in the borrowings limit of the Company 7. Creation of Mortgage/Charge on the Assets of the Company 8. Notice of Postal Ballot Medico Remedies Ltd - 540937 - Board Meeting Intimation for Adoption Of Audited Financial Results For The Half-Year Ended 31St March, 2022 And Audited Financial Statement For The Year Ended 31St March, 2022
Medico Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2022 ,inter alia, to consider and approve 1.To consider and approve, Audited Financial Results for the half year ended 31st March, 2022 and Audited Financial Statements for the year ended on 31st March, 2022; and 2. Any other business with the permission of the Chair Medico Remedies Ltd - 540937 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayMedico Remedies Ltd 2CINL24230MH1994PLC077187 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 9.69 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: DINESH MODI Designation: COMPANY SECRETARY EmailId: secretarialmrl@gmail.com Name of the Chief Financial Officer: HARESH MEHTA Designation: CHAIRMAN AND WTD CFO EmailId: hareshmehta1955@gmail.com Date: 29/04/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.